HCV-related hepatocellular carcinoma: From chronic inflammation to cancer

Clinical Immunology

Volumn 134, Issue 3, 2010, Pages 237-250

  Castello, Giuseppe ^a   Scala, Stefania ^b   Palmieri, Giuseppe ^c   Curley, Steven A ^d   Izzo, Francesco ^b  

^a Oncology Research Centre (Centro Ricerche Oncologiche di Mercogliano CROM)   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Immune response; Inflammation

Indexed keywords

CYTOKINE;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CHRONIC INFLAMMATION; EPIGENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR; TUMOR ESCAPE; VIRUS CARCINOGENESIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER NEOPLASMS; MALE;

EID: 76049097477     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.10.007     Document Type: Review

References (153)

1. American Cancer Society. Age-standardized liver cancer incidence rates. Global Cancer Facts & Figures 2007 (2007), Atlanta, Georgia 18-23
2. Perz J.F., Armstrong GL., Farrington L.A., Hutin Y.J., and Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45 4 (2006) 529-538
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics 2009. CA Cancer J. Clin. 59 (2009) 225-249
4. Altekruse S.F., McGlynn K.A., and Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27 (2009) 1485-1491
5. Bosetti C., Levi F., Boffetta P., Lucchini F., Negri E., and La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 48 1 (2008) 137-145
6. Fusco M., Girardi E., Piselli P., Palombino R., Polesel J., Maione C., Scognamiglio P., Pisanti F.A., Solmone M., Di Cicco P., Ippolito G., Franceschi S., Serraino D., and Collaborating Study Group. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur. J. Cancer 44 6 (2008) 847-853
7. Fusco M., Palombino R., and Montella M. Naples cancer registry. In: Zanetti R., et al. (Ed). (e mortality mortality ds): Cancer in Italy: incidence data from Cancer Registries, Third Volume: 1993-1998 (2002), Il Pensiero Scientifico Editore, Roma
8. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6 9 (2006) 674-687
9. Lorusso G., and Riegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130 (2008) 1091-1103
10. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27 (2008) 5904-5912
11. Alter H.J., and Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20 (2000) 17-35
12. Lai M.E., Mazzoleni A.P., and Argiolu F. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343 (1994) 388-390
13. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85 (2004) 3173-3188
14. Elias A.P., and Dias S. Microenvironment changes (in pH) affect VEGF alternative splicing. Cancer Microenviron. 1 (2008) 131-139
15. Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenviron. 1 (2008) 113-129
16. Bichr S., Rende-Fournier R., Vona G., Yamamoto A.M., Depla E., Geert Maertens G., and Christian Bréchot C. Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model. J. Gen. Virol. 83 (2002) 1673-1678
17. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25 27 (2006) 3834-3847
18. Golden-Mason L., and Rosen H.R. Natural killer cells: primary target for hepatitis C virus immune evasion strategies?. Liver Transplant. 12 3 (2006) 363-372
19. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 7053 (2005) 946-952
20. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194 10 (2001) 1395-1406
21. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., and Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. U. S. A 26 99(24) (2002) 15661-15668
22. Chang J.J., and Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell Biol. 85 1 (2007) 16-23
23. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., Schiff E.R., Goodman Z.D., Laughlin M., Yao R., and Albrecht J.K. Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
24. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
25. Aghemo A., Rumi M.G., Monico S., Prati G.M., D'Ambrosio R., Donato M.F., and Colombo M. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir. Ther. 14 4 (2009) 577-584
26. Marotta P., Hueppe D., Zehnter E., Kwo P., and Jacobson I. Efficacy of chronic hepatitis C therapy in community-based trials. Clin. Gastroenterol. Hepatol. 7 10 (2009) 1028-1036
27. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 5386 (1998) 103-107
28. Llovet J.M., and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 4 (2008) 1312-1327
29. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., and Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 1 (1998) 68-77
30. Tanaka S., Mori M., Sakamoto Y., Makuuchi M., Sugimachi K., and Wands J.R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J. Clin. Invest. 103 3 (1999) 341-345
31. Mitsuhashi N., Shimizu H., Ohtsuka M., Wakabayashi Y., Ito H., Kimura F., Yoshidome H., Kato A., Nukui Y., and Miyazaki M. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37 5 (2003) 1105-1113
32. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31 4 (2002) 339-346
33. Ozturk N., Erdal E., Mumcuoglu M., Akcali K.C., Yalcin O., Senturk S., Arslan-Ergul A., Gur B., Yulug I., Cetin-Atalay R., Yakicier C., Yagci T., Tez M., and Ozturk M. Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proc. Natl. Acad. Sci. U. S. A. 103 7 (2006) 2178-2183
34. Moradpour D., and Wands J.R. The molecular pathogenesis of hepatocellular carcinoma. J. Viral Hepatitis 1 1 (1994) 17-31
35. Moradpour D., and Blum H.E. Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17 5 (2005) 477-483
36. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumours. Oncogene 25 27 (2006) 3778-3786
37. Matsuda Y. Molecular mechanism underlying the functional loss of cyclin dependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J. Gastroenterol. 14 11 (2008) 1734-1740
38. Pomerantz J., Schreiber-Agus N., Liégeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., and DePinho R.A. The Ink4a tumour suppressor gene product, 19Arf, interacts with MDM2 and neutralizes DM2's inhibition of p53. Cell 92 6 (1998) 713-723
39. Palmieri G., Casula M., Sini M.C., Ascierto P.A., and Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J. Cell. Mol. Med. 11 5 (2007) 1052-1068
40. Chin R., Earnest-Silveira L., Koeberlein B., Franz S., Zentgraf H., Dong X., Gowans E., Bock C.T., and Torresi J. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J. J. Hepatol. 47 3 (2007) 325-337
41. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., Factor V.M., and Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 4 (2006) 1117-1128
42. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., Reis H., Cicinnati V.R., Schmid K.W., and Baba H.A. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 48 1 (2008) 83-90
43. Huynh H., Nguyen T.T., Chow K.H., Tan P.H., Soo K.C., and Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumour progression and apoptosis. BMC Gastroenterol. 3 (2003) 19
44. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93 (2001) 1062-1074
45. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 6892 (2002) 949-954
46. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., Hauss J., and Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 5 (2003) 706-712
47. Lee H.C., Tian B., Sedivy J.M., Wands J.R., and Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131 4 (2006) 1208-1217
48. Lengauer C., Kinzier K.W., and Volgestein B. Genetic instabilities in human cancers. Nature 396 6712 (1998) 643-649
49. Edamoto Y., Hara A., Biernat W., Terracciano L., Cathomas G., Riehle H.M., Matsuda M., Fujii H., Scoazec J.Y., and Ohgaki H. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 106 3 (2003) 334-341
50. Koike K. Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol. Res. 37 Suppl. 2 (2007) S115-S120
51. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., Gupta S., Moore J., Wrobel M.J., Lerner J., Reich M., Chan J.A., Glickman J.N., Ikeda K., Hashimoto M., Watanabe G., Daidone M.G., Roayaie S., Schwartz M., Thung S., Salvesen H.B., Gabriel S., Mazzaferro V., Bruix J., Friedman S.L., Kumada H., Llovet J.M., and Golub T.R. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359 19 (2008) 1995-2004
52. Svegliati-Baroni G., De Minicis S., and Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int. 28 8 (2008) 1052-1064
53. Sher A., Pearce E., and Kaye P. Shaping the immune response to parasites: role of dendritic cells. Curr. Opin. Immunol. 15 4 (2003) 421-429
54. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
55. Canning C., O ' Brien M., Hegarty J., and O ' Farrelly C. Liver immunity and tumour surveillance. Immunol. Lett. 107 2 (2006) 83-88
56. Tosi M.F. Innate immune responses to infection. J. Allergy Clin. Immunol. 116 2 (2005) 241-249 quiz 250
57. Thompson J.M., and Iwasaki A. Toll-like receptors regulation of viral infection and disease. Adv. Drug Deliv. Rev. 60 7 (2008) 786-794
58. Malmgaard L. Induction and regulation of IFNs during viral infections. J. Interferon. Cytokine Res. 24 8 (2004) 439-454
59. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
60. Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 55 (2001) 255-281
61. Richmond A. NF-kappaB, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2 9 (2002) 664-674
62. Tai D.I., Tsai S.L., Chen Y.M., Chuang Y.L., Peng C.Y., Sheen I.S., Yeh C.T., Chang K.S., Huang S.N., Kuo G.C., and Liaw Y.F. Activation of nuclear factor-κB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 31 3 (2000) 656-664
63. Tilg H. New insights into the mechanisms of interferon α: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112 3 (1997) 1017-1021
64. Chiesa M.D., Sivori S., Castriconi R., et al. Pathogen-induced private conversations between natural killer and dendritic cells. Trends Microbiol. 13 (2005) 128-136
65. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., and Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000) 767-811
66. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., and Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194 6 (2001) 863-869
67. Jinushi M., Takehara T., Kanto T., Tatsumi T., Groh V., Spies T., Miyagi T., Suzuki T., Sasaki Y., and Hayashi N. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J. J. Immunol. 170 3 (2003) 1249-1256
68. Kanto T., and Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern. Med. 45 4 (2006) 183-191
69. Chan-Fook C., Jiang W.R., Clarke B.E., Zitzmann N., Maidens C., McKeating J.A., and Jones I.M. Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity. Virology 273 (2000) 60-66
70. Tseng C.T., and Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195 1 (2002) 43-49
71. Matsui T., Nagai H., Sumino Y., and Miki K. Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis. Cancer Chemother. Pharmacol. 62 3 (2008) 401-406
72. Guidotti L.G., and Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19 (2001) 65-91
73. Frese M., Schwärzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., and Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 3 (2002) 694-703
74. Umetsu D.T., Akbari O., and Dekruyff R.H. Regulatory T cells control the development of allergic disease and asthma. J. Allergy Clin. Immunol. 112(3) (2003) 480-487 quiz 488
75. Budhu A., and Wang X.W. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 80 6 (2006) 1197-1213
76. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., and Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98 3 (1996) 706-714
77. Cerny A., and Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30 3 (1999) 595-601
78. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., Hoffmann R., Schirren C.A., Santantonio T., and Pape G.R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T cell response in acute hepatitis C. Gastroenterology 117 4 (1999) 933-941
79. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., Chung R.T., and Walker B.D. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76 24 (2002) 12584-12595
80. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., and Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
81. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., and Walker C.M. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197 12 (2003) 1645-1655
82. Lechner F., Gruener N.H., Urbani S., Uggeri J., Santantonio T., Kammer A.R., Cerny A., Phillips R., Ferrari C., Pape G.R., and Klenerman P. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur. J. Immunol. 30 9 (2000) 2479-2487
83. He X.S., Rehermann B., López-Labrador F.X., Boisvert J., Cheung R., Mumm J., Wedemeyer H., Berenguer M., Wright T.L., Davis M.M., and Greenberg H.B. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. U. S. A. 96 10 (1999) 5692-5697
84. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., and Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191 9 (2000) 1499-1512
85. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., and Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 5645 (2003) 659-662
86. McGuinness P.H., Painter D., Davies S., and McCaughan G.W. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46 2 (2000) 260-269
87. MacDonald A.J., Duffy M., Brady M.T., McKiernan S., Hall W., Hegarty J., Curry M., and Mills K.H. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J. Infect. Dis. 185 6 (2002) 720-727
88. Semmo N., Day C.L., Ward S.M., Lucas M., Harcourt G., Loughry A., and Klenerman P. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 41 5 (2005) 1019-1028
89. Sugimoto K., Ikeda F., Stadanlick J., Nunes F.A., Alter H.J., and Chang K.M. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38 6 (2003) 1437-1448
90. Cabrera R., Tu Z., Xu Y., Firpi R.J., Rosen H.R., Liu C., and Nelson D.R. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 5 (2004) 1062-1071
91. Boettler T., Spangenberg H.C., Neumann-Haefelin C., Panther E., Urbani S., Ferrari C., Blum H.E., von Weizsäcker F., and Thimme R. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J. Virol. 79 12 (2005) 7860-7867
92. Ormandy L.A., Hillemann T., Wedemeyer H., and Manns M.P. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65 6 (2005) 2457-2464
93. Accapezzato D., Francavilla V., Rawson P., Cerino A., Cividini A., Mondelli M.U., and Barnaba V. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. Eur. J. Immunol. 34 2 (2004) 438-446
94. J onuleit H., Schmitt E., Kakirman H., Stassen M., Knop J., and Enk A.H. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J. Exp. Med. 196 2 (2002) 255-260
95. Dieckmann D., Bruett C.H., Ploettner H., Lutz M.B., and Schuler G. Human CD4(+)CD25(+) regulatory, contact dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J. Exp. Med. 196 2 (2002) 247-253
96. Huang Y.S., Hwang S.J., Chan C.Y., Wu J.C., Chao Y., Chang F.Y., and Lee S.D. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei) 62 6 (1999) 327-333
97. Kakumu S., Okumura A., Ishikawa T., Yano M., Enomoto A., Nishimura H., Yoshioka K., and Yoshika Y. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-(TNF-alpha) receptors in type C chronic liver disease. Clin. Exp. Immunol. 109 3 (1997) 458-463
98. Chia C.S., Ban K., Ithnin H., Singh H., Krishnan R., Mokhtar S., Malihan N., and Seow H.F. Expression of interleukin-18, interferon-gamma and interleukin-10 in hepatocellular carcinoma. Immunol. Lett. 84 3 (2002) 163-172
99. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 70 3 (1992) 709-713
100. Hu R.H., Lee P.H., and Yu S.C. Secretion of acute-phase proteins before and after hepatocellular carcinoma resection. J. Formos Med. Assoc. 98 2 (1999) 85-91
101. Bortolami M., Venturi C., Giacomelli L., Scalerta R., Bacchetti S., Marino F., Floreani A., Lise M., Naccarato R., and Farinati F. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig. Liver Dis. 34 11 (2002) 794-801
102. Zekri A.R., Ashour M.S., Hassan A., Alam El-Din H.M., El Shehaby A.M., and Abu-Shady M.A. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J. Gastroenterol. 11 42 (2005) 6624-6630
103. Wiltrout R.H. Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol. Rev. 174 (2000) 63-76
104. De Lalla C., Galli G., Aldrighetti L., Romeo R., Mariani M., Monno A., Nuti S., Colombo M., Callea F., Porcelli S.A., Panina-Bordignon P., Abrignani S., Casorati G., and Dellabona P. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J. Immunol. 173 2 (2004) 1417-1425
105. Koziel M.J., Dudley D., Wong J.T., Dienstag J., Houghton M., Ralston R., and Walker B.D. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis [published erratum appears in J Immunol 150(6) (1993) 2563]. J. Immunol. 149 (1992) 3339-3344
106. Minutello M.A., Pileri P., Unutmaz D., Censini S., Kuo G., Houghton M., Brunetto M.R., et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD41 T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J. Exp. Med. 178 (1993) 17-25
107. Liaw Y.F., Lee C.S., Tsai S.L., Liaw B.W., Chen T.C., Sheen I.S., and Chu C.M. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 22 (1995) 1368-1373
108. Farci P., Alter H.J., Shimoda A., Govindarajan S., Cheung L.C., Melpolder J.C., Sacher R.A., et al. Hepatitis C virus-associated fulminant hepatic failure. N. Engl. J. Med. 335 (1996) 631-634
109. Brillanti S., Foli M., Gaiani S., Masci C., Miglioli M., and Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 341 (1993) 464-465
110. Hussain S.P., Hofseth L.J., and Harris C.C. Radical causes of cancer. Nat. Rev. Cancer 3 4 (2003) 276-285
111. Majano P.L., and Garcia-Monzon C. Does nitric oxide play a pathogenic role in hepatitis C virus infection?. Cell Death Differ. 10 Suppl. 1 (2003) S13-15
112. Kato N., Yoshida H., Ono-Nita S.K., Kato J., Goto T., Otsuka M., Lan K., Matsushima K., Shiratori Y., and Omata M. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 32 2 (2000) 405-412
113. Choi J., Lee K.J., Zheng Y., Yamaga A.K., Lai M.M.C., and Ou J.H. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39 (2004) 81-89
114. Choi J., and Ou J.H. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am. J. Physiol. Gastrointest. Liver Physiol. 290 5 (2006) G847-851
115. Mahmood S., Kawanaka M., Kamei A., Izumi A., Nakata K., Niiyama G., Ikeda H., Hanano S., Suehiro M., Togawa K., and Yamada G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid. Redox Signal. 6 (2004) 19-24
116. Maki A., Kono H., Gupta M., Asakawa M., Suzuki T., Matsuda M., Fujii H., and Rusyn I. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann. Surg. Oncol. 14 3 (2007) 1182-1190
117. Choi S.H., and Hwang S.B. Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J. Biol. Chem. 281 11 (2006) 7468-7478
118. Izzo F., Montella M., Orlando A.P., Nasti G., Beneduce G., Castello G., Cremona F., Ensor C.M., Holtzberg F.W., Bomalaski J.S., Clark M.A., Curley S.A., Orlando R., Scordino F., and Korba B.E. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J. Gastroenterol. Hepatol. 22 1 (2007) 86-91
119. Parasole R., Izzo F., Perrone F., Pignata S., Galati M.G., Leonardi E., Castiglione F., Orlando R., Castello G., Esposito G., Gallo C., and Daniele B. Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin. Cancer Res. 7 11 (2001) 3504-3509
120. Izzo F., Cremona F., Delrio P., Leonardi E., Castello G., Pignata S., Daniele B., and Curley S.A. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Ann. Surg. Oncol. 6 2 (1999) 178-185 Comment in: Ann Surg Oncol 6(2) 133-134
121. Polyak S.J., McArdle S., Liu S.L., Sullivan D.G., Chung M., Hofgärtner W.T., Carithers Jr. R.L., McMahon B.J., Mullins J.I., Corey L., and Gretch D.R. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72 5 (1998) 4288-4296
122. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., and Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 5464 (2000) 339-344
123. Chevaliez S., and Pawlotsky J.M. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract. Res. Clin. Gastroenterol. 6 (2008) 1031-1048
124. Bain C., Fatmi A., Zoulim F., Zarski J.P., Trépo C., and Inchauspé G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120 2 (2001) 512-524
125. Ulsenheimer A., Gerlach J.T., Jung M.C., Gruener N., Wächtler M., Backmund M., Santantonio T., Schraut W., Heeg M.H., Schirren C.A., Zachoval R., Pape G.R., and Diepolder H.M. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41 3 (2005) 643-651
126. Seifert U., Liermann H., Racanelli V., Halenius A., Wiese M., Wedemeyer H., Ruppert T., Rispeter K., Henklein P., Sijts A., Hengel H., Kloetzel P.M., and Rehermann B. Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. 114 2 (2004) 250-259
127. Crotta S., Stilla A., Wack A., D'Andrea A., Nuti S., D'Oro U., Mosca M., Filliponi F., Brunetto R.M., Bonino F., Abrignani S., and Valiante N.M. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195 1 (2002) 35-41
128. Kamal S.M., Fehr J., Roesler B., Peters T., and Rasenack J.W. Peg-interferon alone or with ribavirin enhances HCV-specific CD4 T helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123 4 (2002) 1070-1083
129. Barnes E., Harcourt G., Brown D., Lucas M., Phillips R., Dusheiko G., and Klenerman P. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36 3 (2002) 743-754
130. Sarobe P., Lasarte J.J., Casares N., López-Díaz de Cerio A., Baixeras E., Labarga P., García N., Borrás-Cuesta F., and Prieto J. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol. 76 10 (2002) 5062-5070 Erratum in: J Virol. 138(1) (2004) 193
131. Dolganiuc A., Kodys K., Kopasz A., Marshall C., Do T., Romics Jr. L., Mandrekar P., Zapp M., and Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 170 11 (2003) 5615-5624
132. Brady M.T., MacDonald A.J., Rowan A.G., and Mills K.H. Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur. J. Immunol. 33 12 (2003) 3448-3457
133. Zhang J., Randall G., Higginbottom A., Monk P., Rice C.M., and McKeating J.A. CD81 is required for hepatitis C virus glycoprotein mediated viral infection. J. Virol. 78 3 (2004) 1448-1455
134. Francavilla V., Accapezzato D., De Salvo M., Rawson P., Cosimi O., Lipp M., Cerino A., Cividini A., Mondelli M.U., and Barnaba V. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur. J. Immunol. 34 2 (2004) 427-437
135. Lucas M., Vargas-Cuero A.L., Lauer G.M., Barnes E., Willberg C.B., Semmo N., Walker B.D., Phillips R., and Klenerman P. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J. Immunol. 172 3 (2004) 1744-1753
136. Crispe I.N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3 1 (2003) 51-62
137. Lau A.H., and Thomson A.W. Dendritic cells and immune regulation in the liver. Gut 52 2 (2003) 307-314
138. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
139. Corazza N., Badmann A., and Lauer C. Immune cell-mediated liver injury. Semin. Immunopathol. (2009 Jun 17) [Epub ahead of print]
140. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., Mushahwar I.K., Desai S.M., Miller R.H., Ogata N., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 (1992) 135-140
141. Waggoner S.N., Hall C.H., and Hahn Y.S. HCV core protein interaction with gC1q receptor inhibits TH1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J. Leukoc. Biol. 82 (2007) 1407-1419
142. Wang H., and Eckels D.D. Mutations in immunodominant T-cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T-cell recognition. J. Immunol. 162 (1999) 4177-4183
143. Ulsenheimer A., Gerlach J.T., Gruener N.H., et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 37 (2003) 1189-1198
144. Wang J.H., Layden T.J., and Eckels D.D. Modulation of the peripheral T-cell response by CD4 mutants of hepatitis C virus: transition from a TH1 to a TH2 response. Hum. Immunol. 64 (2003) 662-673
145. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., Liang T.J., Alter H., and Rehermann B. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169 (2002) 3447-3458
146. Penna A., Pilli M., Zerbini A., Orlandini A., Mezzadri S., Sacchelli L., Missale G., and Ferrari C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45 (2007) 588-601
147. Spangenberg H.C., Viazov S., Kersting N., Neumann-Haefelin C., McKinney D., Roggendorf M., von Weizsäcker F., Blum H.E., and Thimme R. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 42 (2005) 828-837
148. Neumann-Haefelin C., Timm J., Spangenberg H.C., Wischniowski N., Nazarova N., Kersting N., Roggendorf M., Allen T.M., Blum H.E., and Thimme R. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 47 (2008) 1824-1836
149. Pawlotsky J.M. Diagnostic tests for hepatitis C. J. Hepatol. 31 Suppl. 1 (1999) 71-79
150. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., and Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest. 106 10 (2000) 1239-1249
151. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 3 (2005 Mar) 215-229
152. Bertolino P., McCaughan G.W., and Bowen D.G. Role of primary intrahepatic T-cell activation in the "liver tolerance effect". Immunol. Cell Biol. 80 1 (2002 Feb) 84-92
153. Rushbrook S.M., Ward S.M., Unitt E., Vowler S.L., Lucas M., Klenerman P., and Alexander G.J. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J. Virol. 79 12 (2005) 7852-7859